Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80187 |
Name | chronic neutrophilic leukemia |
Definition | A chronic leukemia characterized by neutrophilic leukocytosis with no detectable Philadelphia chromosome or BCR/ABL fusion gene. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia chronic leukemia chronic neutrophilic leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
CSF3R S783fs | Dasatinib | chronic neutrophilic leukemia | predicted - sensitive | detail... |
CSF3R S783fs | Pyridone 6 | chronic neutrophilic leukemia | predicted - resistant | detail... |
CSF3R S783fs | Tofacitinib | chronic neutrophilic leukemia | predicted - resistant | detail... |
CSF3R S783fs | Momelotinib | chronic neutrophilic leukemia | predicted - resistant | detail... |
CSF3R N579Y CSF3R Q739* CSF3R Q741* | Ruxolitinib | chronic neutrophilic leukemia | predicted - sensitive | detail... |
CSF3R T618I CSF3R Q749* | Ruxolitinib | chronic neutrophilic leukemia | predicted - sensitive | detail... |
CSF3R T618I | Ruxolitinib | chronic neutrophilic leukemia | predicted - sensitive | detail... |
CSF3R T640N | Ruxolitinib | chronic neutrophilic leukemia | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02092324 | Phase II | Ruxolitinib | Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia | Completed | USA | 0 |
NCT03862157 | Phase Ib/II | Azacitidine + MLN4924 + Venetoclax | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT05177211 | Phase II | Fedratinib | Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) | Active, not recruiting | USA | 0 |